Longitudinal algorithm may detect ovarian cancer earlier

Share this article:
Longitudinal Algorithm May Detect Ovarian Cancer Earlier
Longitudinal Algorithm May Detect Ovarian Cancer Earlier

(HealthDay News) -- Compared with a single-threshold (ST) rule, a parametric empirical Bayes (PEB) longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

Charles W. Drescher, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared an ST rule with a PEB longitudinal screening algorithm in a retrospective evaluation of preclinical CA125 values measured annually in 44 participants with incident ovarian cancer from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The researchers found that, in many cases, ovarian cancer was detected earlier using the PEB algorithm, compared to using an ST rule. At a specificity of 99 percent, corresponding to an ST rule CA125 cut-off of ≥35 U/mL used in the PLCO trial, use of the PEB algorithm would have identified 20 percent of cases earlier. The PEB indicated abnormal CA125 values among these cases 10 months earlier and at a lower CA125 concentration (42 percent lower; 20 U/mL) than an ST rule cut-off. As the specificity of screening was reduced, there was an increase in the proportion of cases detected earlier by PEB.

"Our results demonstrated that, for ovarian cancer screening by using CA125, the PEB longitudinal algorithm detected ovarian cancer earlier than an ST rule in a statistically significant and meaningful proportion of cases," the authors write. "This observation was consistent across a range of specificities relevant for a first-line test in a multimodal screening program."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.

Overdetection of PSA recurrence after radical prostatectomy more likely in older patients

Overdetection of PSA recurrence after radical prostatectomy more ...

For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.